PPH

Launch of two first-in-class medicines in 2023 marks start of exciting phase of growth for Ferring

Retrieved on: 
Tuesday, April 9, 2024
Research, Clinical Trials, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Oncology, Other Science, CER, Nadofaragene firadenovec, AER, Audit, Growth, Alexandra, Countess of Frederiksborg, Ferring, Falk, Partnership, ESG, Mortality, Nordic Investment Bank, PPH, Committee on Finance, Annual report, Count, Vice, Food, Management

EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.

Key Points: 
  • EBITDA increased by +€43 million (+12% at AER) to reach €406 million and operating profit for the year reached €139 million.
  • The year marked a major turning-point for Ferring with the launch of two innovative first-in-class medicines in the United States.
  • Ferring is evolving to make the most of these opportunities, and there were a number of significant changes to the senior leadership.
  • Jean-Frédéric Paulsen, Chairman of the Board of Directors, said: “The launch of two groundbreaking medicines in the US, along with the other important changes in 2023, mark the start of an exciting new phase of growth for Ferring.

PharmAla-1 Molecule Receives US Patent Prosecution Highway Acceptance

Retrieved on: 
Monday, January 8, 2024
MDXX, Conference, Partnership, PPH, PCT, Research, Patent, MDMA, University, Innovation, Patient, Safety, P-1, OTC, United States patent law, Pharmacology, Patent Cooperation Treaty, Pharmaceutical industry

“The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.

Key Points: 
  • “The dawn of MDMA as a therapeutic molecule is just beginning, and while we are actively working to treat patients with that molecule, we are also looking towards a future with novel molecular assets,” said Nick Kadysh, CEO, PharmAla Biotech.
  • “P-1 is one of a number of next-generation assets which we are developing, and which promise to bring together both increased safety, and highly beneficial effects like increased neuroplasticity.”
    The Patent Prosecution Highway (PPH) speeds up the examination process for corresponding applications filed in participating intellectual property offices.
  • Under PPH, participating patent offices have agreed that when an applicant receives a ruling from a first patent office indicating that at least one claim is allowable, the applicant may request fast track examination of corresponding claims.
  • Proof-of-concept testing for P-1 showed significant efficacy and pro-social effect at dosage levels far lower than MDMA, PharmAla’s primary comparator molecule, as well as excellent safety pharmacology.

Positive opinion from ISA-Israel patent office Provides the ability to file a patent application under the Patent Prosecution Highway (PPH) in the US

Retrieved on: 
Monday, December 18, 2023
Invention, Partner, PPH, PCT, Patent, BYND, BCAN, IP, European Patent Convention, EPO, 3D printing

A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.

Key Points: 
  • A national phase application corresponding to inventive concept III of PCT/IL2022/050783 was filed on December 7, 2023, as a U.S. utility patent application under the Patent Prosecution Highway (PPH) and has been allocated the application number 18/567,766.
  • The Company also announced filing in 11 additional jurisdictions, including the European Patent Office (EPO), which includes 38 European countries.
  • The Company has strategically pursued accelerated processing through the Patent Prosecution Highway (PPH) for one of its inventions, aligning with international efforts to promote work-sharing among patent offices.
  • The Company is actively collaborating with legal experts, including Reinhold Cohn and Partners, to navigate the complex landscape of patent prosecution and ensure optimal outcomes.

First Real-World Observational Study of the JADA® System, a Medical Device to Control Postpartum Hemorrhage (PPH), Published in ACOG’s Obstetrics & Gynecology

Retrieved on: 
Thursday, September 14, 2023
Women, Biotechnology, Pharmaceutical, General Health, Health, Medical Devices, Consumer, Clinical Trials, Columbia University, Columbia University Irving Medical Center, Internal bleeding, JADA, RBC, Society, ACOG, Obstetrics, PPH, Trial of the century, Obstetrics and gynaecology, Record, Woman, Multimedia, OGN, Hospital, Bleeding, Patient, Hysterectomy, Department of Obstetrics and Gynecology (Massachusetts General Hospital), ICU, American College, SMM, NYSE, Birth control, Gynaecology, Organon

Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1

Key Points: 
  • Organon (NYSE: OGN), a global healthcare company focused on improving women’s health, today announced that Obstetrics & Gynecology (“The Green Journal”), the peer-reviewed journal of the American College of Obstetrics and Gynecology (ACOG), published the results of the RUBY study ( NCT04995887 ) which reached its primary effectiveness outcome of successfully treating abnormal postpartum uterine bleeding and postpartum hemorrhage (PPH) with the JADA® System.1 JADA is an intrauterine vacuum-induced hemorrhage control device intended to provide control and treatment of abnormal postpartum uterine bleeding or hemorrhage when conservative management is warranted.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20230913796173/en/
    “PPH is a potentially life-threatening obstetric emergency that can occur after childbirth and requires timely medical intervention.1,6 Appropriate management of abnormal postpartum uterine bleeding is critical to minimize the potential clinical consequences of PPH7 and its associated severe maternal morbidities, such as the need for blood transfusions, ICU admission or hysterectomy,”1,8,9 said lead author Dena Goffman, M.D., a maternal-fetal medicine subspecialist, and professor and vice chair for quality and patient safety in the Department of Obstetrics and Gynecology at Columbia University Irving Medical Center in New York.
  • “The new study, which included a larger population than the pivotal trial, showed how the device is being used outside of a controlled clinical trial environment.
  • Secondary outcome measures, including time to bleeding control, in-dwelling time, total blood loss and red blood cell transfusions, were also presented.

Pushpay’s Annual State of Church Tech Report Shows Refined Use of Ministry Tools Among Catholic Churches

Retrieved on: 
Monday, April 3, 2023
St. Michael's Church, PPH, Catholic Church, Renewal, CFR, ASX, Mobile, Social media, Traction, Heel, NZSX, Digital, Annual report, Franciscans, Software, Video game, Cryptocurrency, Metaverse, Mass

“As leaders in the Catholic Church, we are living in an unparalleled time of change and challenge,” said Fr.

Key Points: 
  • “As leaders in the Catholic Church, we are living in an unparalleled time of change and challenge,” said Fr.
  • The average number of digital tools used by parishes decreased significantly since 2021—from 7.9 to 6.5 tools.
  • Looking ahead, church management and donor management software were chosen as the top ministry tools for the future.
  • The release of the Catholic State of Church Tech report comes on the heels of several recent product innovations and enhancements to ParishStaq , Pushpay’s purpose-built technology suite for parishes and dioceses.

Pushpay Announces New Product Innovations to Help Streamline Ministry Operations and Increase Engagement in the Church

Retrieved on: 
Thursday, March 30, 2023
Online, Tehran Research and Planning Center, Sermon, PPH, ASX, Research, Florida State University School, Vimeo, Acquisition, PCO, NZSX, Catholic Church, Saint Anthony, Mobile phone, Online shopping, Church

Today the Company announced an enhanced global navigation experience, which further unifies its products across all digital platforms.

Key Points: 
  • Today the Company announced an enhanced global navigation experience, which further unifies its products across all digital platforms.
  • Pushpay continues to innovate and deliver technology that meets the growing needs of the Church in a digital era.
  • In fact, Pushpay research shows the significant role technology plays in the Church today, with 94 percent indicating that technology is important to helping them achieve their mission.
  • New capabilities also help improve financial planning confidence for the Church, and supports them in achieving pledge campaign goals.

Pushpay’s Customer Success Team Wins Contact Center of the Year at the 2023 Stevie® Awards

Retrieved on: 
Friday, March 10, 2023
Stevie Awards, NZSX, Gold, Heart, ASX, Caesars Palace, International business, City centre, PPH, Growth, Customer, Success, Customer service, Organization, American Business Women's Association, Heel, Video game

The Company also received bronze awards in Customer Service Department of the Year and National Sales Team of the Year categories.

Key Points: 
  • The Company also received bronze awards in Customer Service Department of the Year and National Sales Team of the Year categories.
  • “Our Customer Success team in particular has deployed new tools and strategies this year to help streamline support and enhance the customer experience.”
    The 2023 Stevie Awards for Sales and Customer Service are the world’s top honors for customer service, contact center, business development, and sales professionals.
  • The Stevie Awards also organizes eight of the world’s leading business awards programs, including the American Business Awards® and International Business Awards®.
  • This year there were more than 2,300 nominations from organizations of varying sizes, industries and geographic locations—including 49 nations and territories—that were considered in the sales and customer success awards competition.

Approval of New Medicines in 2022 Sets Ferring on Course for Future Growth and Diversification

Retrieved on: 
Thursday, March 9, 2023
Biotechnology, FDA, Health, Pharmaceutical, Oncology, US Foods, World Health Organization, Ferring Pharmaceuticals, Center for Biologics Evaluation and Research, Research, Growth, Woman, Maternal health, Menotropin, Patient, Annual report, Multimedia, Nadofaragene firadenovec, Bladder cancer, COVID-19, PPH, Safety, Reproductive medicine, Pharmaceutical industry

View the full release here: https://www.businesswire.com/news/home/20230308005673/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230308005673/en/
    Approval of new medicines in 2022 sets Ferring on course for future growth and diversification (Photo: Business Wire)
    The main highlights of the year were the approvals by the US Food and Drug Administration (FDA) for two pioneering new medicines, Rebyota™ (fecal microbiota, live – jslm), a new microbiome treatment, and Adstiladrin® (nadofaragene firadenovec-vncg), a novel gene-based therapy for bladder cancer.
  • These were approved in November and December 2022 respectively.
  • Carbetocin Ferring (carbetocin, room temperature-stable formulation) became our first-ever product to gain prequalification status from the World Health Organization.
  • The appreciation of several currencies against the euro resulted in revenues achieving growth of +5% at actual exchange rates.

Global Polypropylene (PP) Market Report 2023: Exponentially Rising Demand for Electric and Hybrid Vehicles Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 7, 2023
Chemicals, Plastics, Automotive, EV, Electric Vehicles, Manufacturing, Alternative Energy, Energy, INEOS, Electronics, LyondellBasell, Nature, BOPP, Fatigue, Polymerization, Polypropylene, PPC, Growth, Construction, ExxonMobil, Food packaging, Textile, Consumer, PP, Indian Oil Corporation, Food, Polymer, Process, PPH, Nayara Energy, Reliance Industries, International trade, Health, Agriculture, Thermoplastic, Wood-plastic composite, Chemical, Risk management, Vadinar, Polyethylene

The packaging industry dominates the Polypropylene market and is the most widely used plastic for packaging and largely used in food packaging applications.

Key Points: 
  • The packaging industry dominates the Polypropylene market and is the most widely used plastic for packaging and largely used in food packaging applications.
  • The increasing demand for Polypropylene by the automotive industry is expected to boost the Polypropylene market in the forecast period.
  • Exponentially rising demand for electric and hybrid electric vehicles (EV/HEV) is further propelling the demand for Polypropylene and is likely to augment the market growth in the future.
  • This industry is anticipated to dominate the global Polypropylene (PP) market owing to the growing demand of ready-to-eat food items in the forthcoming years.

Pushpay’s 2023 State of Technology Report Reveals Hybrid Church Is Here to Stay

Retrieved on: 
Wednesday, March 1, 2023
Geographic Locator Codes, Social media, St. Michael's Church, ASX, Privacy, Research, Mosaic (church), NZSX, History, PPH, Catholic Church, Digital, United, Florida State University School, Management, Music, Metaverse, Pushpay, Church

Insights reveal priorities, concerns, and expectations of church leaders, so ministry leaders can explore the latest digital trends and see data-driven insights about the future of church technology.

Key Points: 
  • Insights reveal priorities, concerns, and expectations of church leaders, so ministry leaders can explore the latest digital trends and see data-driven insights about the future of church technology.
  • In fact, more than half of churches (53%) consider themselves progressive when it comes to technology adoption and usage today.
  • “Most of the time we hear about how the church is resistant to change and to the modernization of technology.
  • Church-specific tools are on the rise: 86% of church leaders report they do not want more technology tools.